TRANSCEND-CKD (NCT05936151) is a Phase 2b double-blind, placebo-controlled mechanistic trial designed to isolate retatrutide's effect on eGFR slope in adults with obesity and CKD. Its design separates acute hemodynamic dips from chronic slope, enrolls CKD stages 2–4, and stratifies by T2D status — giving it a credible structural basis for attributing eGFR changes to retatrutide. Efficacy results remain pending.
What Is the TRANSCEND-CKD Trial and Why Was It Designed as a Mechanistic Study?
TRANSCEND-CKD is a Phase 2b mechanistic study, not a hard-endpoint outcomes trial. Its primary objective is to characterise how retatrutide alters kidney function and structure in adults with CKD — generating the data needed to determine whether a larger Phase 3 kidney-outcomes programme is warranted. The design paper (Heerspink et al., NDT 2026) frames this as a hypothesis-generating platform.
The trial is registered as NCT05936151, designed by Hiddo Heerspink's group at the University of Groningen in collaboration with Eli Lilly. It enrolls adults with BMI ≥27 kg/m² and CKD stages 2–4, with or without T2D, provided HbA1c is ≤9.5%. T2D must be managed with diet, exercise, or up to three oral antidiabetic agents.
SGLT2 inhibitors and GLP-1 receptor agonists are excluded from background therapy. The design paper was published in Nephrology Dialysis Transplantation in 2026 (doi: 10.1093/ndt/gfaf230). Retatrutide is administered as once-weekly subcutaneous injections, with dose escalation schedules mirroring those used in the TRIUMPH obesity programme.
The mechanistic framing is deliberate. A Phase 2b mechanistic study can use eGFR slope as a primary endpoint with a smaller sample size than a hard-endpoint trial requiring kidney failure or sustained 40% eGFR decline. This design choice reflects the nephrology field's validated use of total GFR slope as a surrogate endpoint, supported by meta-analyses demonstrating its predictive validity for end-stage kidney disease.
How Does the eGFR Slope Endpoint Separate True Renoprotection from Hemodynamic Noise?
The eGFR slope endpoint in TRANSCEND-CKD distinguishes the acute hemodynamic dip — a transient eGFR shift seen early in many renoprotective agents — from the chronic slope reflecting structural kidney protection. This separation is critical for retatrutide because its GLP-1R component causes afferent arteriolar vasodilation that can transiently alter GFR independent of any disease-modifying effect.
In nephrology trial methodology, the total eGFR slope is decomposed into an acute component (approximately weeks 0–12) and a chronic component (post-acute through end of treatment). The acute component captures hemodynamic effects, including the initial dip seen with SGLT2 inhibitors. The chronic slope captures the rate of structural nephron loss or preservation.
Meta-analyses by Grams et al. (2019) and subsequent FDA guidance established that the chronic eGFR slope is a validated surrogate for ESKD in trials of at least 2–3 years. Shorter mechanistic studies use total slope as a hypothesis-generating measure rather than a definitive surrogate.
For retatrutide specifically, the acute hemodynamic picture is complex. GLP-1R agonism in the kidney dilates the afferent arteriole, which can transiently increase GFR — the opposite of the acute dip seen with SGLT2 inhibitors. The phase 2 post-hoc analysis (Heerspink et al., 2025, PMC12231004) found that higher retatrutide doses were associated with increased eGFR in participants with obesity without T2D, consistent with reversal of obesity-related glomerular hyperfiltration.
TRANSCEND-CKD's design addresses this by pre-specifying the eGFR slope measurement window and including kidney structural biomarkers as secondary endpoints. This enables the trial to distinguish hemodynamic eGFR changes from structural remodelling signals — a distinction the phase 2 post-hoc analysis could not make.
What Mechanistic Rationale Supports Each of Retatrutide's Three Receptor Targets in the Kidney?
Retatrutide's three receptor targets — GLP-1R, GIPR, and GCGR — each have distinct renal expression patterns and functional roles. GLP-1R agonism drives natriuresis and reduces glomerular hyperfiltration via afferent arteriolar effects. GIPR agonism modulates tubular sodium handling with anti-inflammatory effects. GCGR agonism is the most complex: renal GCGR is downregulated in CKD, altering its functional role in the diseased kidney.
GLP-1R is expressed on tubular epithelial cells and renal vasculature. Activation promotes natriuresis by reducing sodium-hydrogen exchanger 3 (NHE3) activity in the proximal tubule, lowering tubuloglomerular feedback-driven afferent tone and reducing intraglomerular pressure. This mechanism is mechanistically analogous to — but distinct from — the SGLT2 inhibitor pathway.
The FLOW trial (Perkovic et al., NEJM 2024) established that GLP-1R agonism with semaglutide reduces kidney failure risk by 24% in T2D patients with CKD, providing clinical proof-of-concept for the GLP-1R renal pathway. GIPR's renal role is less characterised: preclinical data suggest GIPR activation in the proximal tubule reduces oxidative stress and NF-κB-driven inflammatory signalling, potentially attenuating tubular injury independent of hemodynamic effects.
GCGR presents the most interpretive challenge. Wang et al. (2024, Cell Metabolism) demonstrated that renal GCGR expression is downregulated in CKD in both humans and animal models, with this downregulation linked to impaired natriuresis and tubular dysfunction. Retatrutide's GCGR agonism in a kidney with reduced receptor expression may produce attenuated or paradoxical effects — a confound that TRANSCEND-CKD's CKD-specific design is uniquely positioned to characterise.
How Does Substantial Weight Loss Confound the Attribution of eGFR Changes to Direct Renal Mechanisms?
Weight loss of the magnitude produced by retatrutide — up to 24% at 48 weeks in phase 2 obesity trials — independently reverses glomerular hyperfiltration, reduces intraglomerular pressure, and lowers albuminuria through hemodynamic and metabolic pathways. Any eGFR improvement in TRANSCEND-CKD could therefore reflect weight-loss-mediated hemodynamic normalisation rather than direct receptor-mediated renoprotection.
Obesity-related glomerulopathy is characterised by hyperfiltration driven by increased renal plasma flow, reduced afferent arteriolar resistance, and elevated intraglomerular pressure. Weight loss reverses these hemodynamic abnormalities proportionally to the degree of adiposity reduction, independent of any pharmacological mechanism. In the phase 2 post-hoc analysis (Heerspink et al., 2025), the eGFR increase in obesity-without-T2D participants correlated with weight loss magnitude, raising the possibility that the signal was predominantly hemodynamic.
TRANSCEND-CKD attempts to address this confound through two design features. First, it enrolls participants with established CKD stages 2–4, a population in which the hyperfiltration phenotype is less dominant — eGFR changes are more likely to reflect structural disease modification. Second, kidney structural biomarkers are included as secondary endpoints to detect changes that would not be explained by hemodynamic normalisation alone.
Nevertheless, complete separation of weight-loss-mediated and direct receptor-mediated effects is not achievable without a weight-loss-matched control arm. This is a recognised limitation of the TRANSCEND-CKD design, acknowledged in the NDT design paper, and it means the trial's mechanistic conclusions will require careful interpretation against concurrent weight-loss data.
What Did the Phase 2 Post-Hoc Kidney Analysis Show, and What Gaps Does TRANSCEND-CKD Fill?
The 2025 post-hoc analysis of phase 2 retatrutide data (Heerspink et al., PMC12231004) found that higher doses reduced UACR by approximately 28% at 48 weeks in participants with obesity, with larger reductions in T2D+obesity. eGFR increased in obesity-without-T2D at higher doses. These signals were hypothesis-generating, not powered for kidney endpoints, and the population lacked CKD — the gap TRANSCEND-CKD fills.
The phase 2 programme enrolled participants with T2D or obesity but without pre-specified CKD inclusion criteria. The kidney analysis was post-hoc and was not a pre-specified endpoint. UACR reductions at 8 mg reached 28% in the obesity arm, a statistically significant finding that nonetheless carried wide confidence intervals reflecting the exploratory design.
These wide intervals reflect the absence of kidney-endpoint statistical powering in the phase 2 design. TRANSCEND-CKD fills three specific gaps: it enrolls a CKD-enriched population (stages 2–4), uses eGFR slope as a pre-specified primary endpoint with adequate statistical power, and includes kidney structural endpoints that can distinguish hemodynamic from structural effects.
The T2D stratification within TRANSCEND-CKD also addresses a key mechanistic question raised by the phase 2 data: whether retatrutide's kidney effects differ between participants with and without T2D. The phase 2 post-hoc found divergent patterns — UACR reduction dominant in T2D, eGFR increase dominant in obesity-without-T2D — suggesting different mechanistic pathways may be operative in these two populations.
How Does the FLOW Trial Precedent Shape the Interpretation of TRANSCEND-CKD's Design Choices?
The FLOW trial (Perkovic et al., NEJM 2024) established that semaglutide 1 mg once weekly reduced the composite kidney failure endpoint by 24% in T2D patients with CKD. TRANSCEND-CKD is positioned as the retatrutide-specific analogue of pre-FLOW mechanistic work — generating the signal data needed to justify whether a FLOW-scale outcomes trial is warranted for the triple agonist.
FLOW enrolled 3,533 participants with T2D and CKD and used a composite hard endpoint of kidney failure, sustained 50% eGFR decline, or kidney or cardiovascular death over a median 3.4 years. TRANSCEND-CKD, by contrast, is a shorter mechanistic study using eGFR slope as a surrogate. This design cannot generate the hard-endpoint evidence FLOW produced, but can generate mechanistic signal data at a fraction of the cost and timeline.
The FLOW result also contextualises the mechanistic question for retatrutide. Semaglutide's kidney benefit in FLOW was observed on a background of standard-of-care including SGLT2 inhibitors in a substantial proportion of participants. TRANSCEND-CKD excludes SGLT2 inhibitors from background therapy, removing a potentially confounding renoprotective signal and allowing retatrutide's kidney effects to be assessed against a cleaner pharmacological background.
The FLOW precedent raises the question of whether retatrutide's additional GIPR and GCGR agonism adds kidney benefit beyond what GLP-1R agonism alone provides. TRANSCEND-CKD cannot answer this directly — it lacks a GLP-1R monotherapy comparator arm — but its mechanistic biomarker endpoints may generate hypotheses about which receptor pathways are driving the observed eGFR signal.
What Are the Principal Design Limitations That Could Prevent TRANSCEND-CKD from Attributing a True Retatrutide Effect on eGFR?
Three design limitations constrain TRANSCEND-CKD's ability to attribute observed eGFR changes to retatrutide's receptor mechanisms: the absence of a weight-loss-matched control arm, the relatively short treatment duration for eGFR slope as a surrogate, and the SGLT2 inhibitor exclusion, which limits generalisability to real-world CKD populations where these agents are standard of care.
The weight-loss-matched control arm problem is the most fundamental. Without a comparator arm achieving equivalent weight loss through a mechanistically distinct route, any eGFR change in the retatrutide arm cannot be cleanly attributed to receptor-mediated renoprotection versus weight-loss-mediated hemodynamic normalisation. This is an inherent limitation of all GLP-1RA kidney trials in obese populations, not a flaw unique to TRANSCEND-CKD.
The treatment duration is a second constraint. Phase 2b mechanistic studies using eGFR slope typically run 52–104 weeks. At the shorter end of this range, the chronic slope signal may not have fully separated from the acute hemodynamic component — particularly if retatrutide produces a prolonged hemodynamic adjustment period due to its combined GLP-1R and GCGR effects on renal vasculature.
The SGLT2 inhibitor exclusion creates a generalisability gap. Current CKD guidelines recommend SGLT2 inhibitors as standard of care for most patients with CKD and proteinuria. Excluding them produces a cleaner pharmacological signal but means the trial's results apply to a population that does not reflect current clinical practice. Whether retatrutide's kidney effects are additive to SGLT2 inhibitor background therapy remains unanswered by this design.
For context on retatrutide's broader cardiometabolic evidence base, see What Do the 2026 TRIUMPH-1 Topline Data Show for Retatrutide's Weight Loss and Cardiometabolic Endpoints at 80 Weeks? For the semaglutide cardiorenal mechanism review, see What Does the 2026 Comprehensive Review Reveal About Semaglutide's Cardioprotective and Nephroprotective Mechanisms in Cardiorenal Syndrome? For protocol-level context on retatrutide in metabolic disease, see How Is Retatrutide Being Studied in CKD and Obesity Protocols in 2026? For the nutritional and metabolic context of GLP-1 triple agonism in body composition, see How Does Retatrutide's Triple-Receptor Agonism Affect Fat Mass and Metabolic Parameters in Obesity Trials in 2026? What Do 2026 Obesity Analyses Reveal About Retatrutide's Efficacy and Safety Risk-Benefit Profile? What Are the Evidence-Based Dosing Protocols for Retatrutide in the TRIUMPH Phase 3 Trial Versus Tirzepatide in 2026? Is the Retatrutide UTI Signal a True Drug Effect or a Trial-Counting Artifact in 2026 Adverse-Event Data?